Jeil Pharmaceutical Co.,Ltd (KRX: 271980)
South Korea
· Delayed Price · Currency is KRW 14,880
+250 (1.71%)
Oct 8, 2024, 3:30 PM KST
Jeil Pharmaceutical Co.,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Operating Revenue | 700,468 | 726,394 | 722,230 | 700,693 | 691,325 | 671,407 |
| Other Revenue | -0 | -0 | -0 | -0 | -0 | - |
| Revenue | 700,468 | 726,394 | 722,230 | 700,693 | 691,325 | 671,407 |
| Revenue Growth (YoY) | -2.32% | 0.58% | 3.07% | 1.36% | 2.97% | - |
| Cost of Revenue | 528,086 | 542,138 | 565,432 | 545,122 | 535,115 | 520,726 |
| Gross Profit | 172,382 | 184,256 | 156,798 | 155,571 | 156,210 | 150,681 |
| Selling, General & Admin | 131,468 | 131,225 | 128,897 | 125,363 | 118,887 | 120,431 |
| Research & Development | 42,957 | 45,727 | 41,147 | 38,974 | 24,270 | 22,114 |
| Other Operating Expenses | 19,678 | 511.83 | 456.31 | -11.35 | 20.56 | 7,903 |
| Operating Expenses | 193,610 | 175,368 | 170,130 | 165,951 | 143,783 | 151,226 |
| Operating Income | -21,228 | 8,888 | -13,332 | -10,380 | 12,427 | -544.94 |
| Interest Expense | -5,977 | -6,033 | -3,009 | -1,967 | -1,071 | -1,215 |
| Interest & Investment Income | 1,190 | 1,031 | 115.6 | 75.84 | 75.27 | 135.84 |
| Earnings From Equity Investments | - | - | - | 2,516 | 631.53 | 325.68 |
| Currency Exchange Gain (Loss) | 865.34 | -225.05 | 99.93 | 90.65 | -117.08 | 91.86 |
| Other Non Operating Income (Expenses) | -11,925 | -2,359 | 946.33 | -3,311 | 519.54 | 467.9 |
| EBT Excluding Unusual Items | -37,075 | 1,302 | -15,180 | -12,975 | 12,464 | -738.55 |
| Gain (Loss) on Sale of Investments | -120.84 | 614.01 | 1,923 | -506.61 | 88.52 | 181.71 |
| Gain (Loss) on Sale of Assets | -2.52 | 0.53 | 9.99 | 30 | -0.95 | 2.73 |
| Asset Writedown | - | - | - | -382 | - | - |
| Pretax Income | -37,198 | 1,916 | -13,247 | -13,834 | 12,552 | -554.12 |
| Income Tax Expense | 1,238 | -3,284 | 1,762 | 1,152 | 5,587 | 9,685 |
| Earnings From Continuing Operations | -38,436 | 5,201 | -15,009 | -14,986 | 6,965 | -10,239 |
| Minority Interest in Earnings | 2,697 | -195.83 | 1,918 | 2,512 | -48.68 | - |
| Net Income | -35,739 | 5,005 | -13,091 | -12,473 | 6,916 | -10,239 |
| Net Income to Common | -35,739 | 5,005 | -13,091 | -12,473 | 6,916 | -10,239 |
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 |
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 |
| Shares Change (YoY) | -0.01% | -0.02% | -0.23% | -0.04% | -0.41% | - |
| EPS (Basic) | -2452.65 | 343.46 | -898.19 | -853.81 | 473.24 | -697.75 |
| EPS (Diluted) | -2453.00 | 343.00 | -898.19 | -853.81 | 473.24 | -698.00 |
| Free Cash Flow | -7,410 | -11,077 | -26,232 | 13,756 | -21,457 | 27,872 |
| Free Cash Flow Per Share | -508.55 | -760.21 | -1799.81 | 941.63 | -1468.17 | 1899.30 |
| Dividend Per Share | 50.000 | 50.000 | 50.000 | - | - | - |
| Gross Margin | 24.61% | 25.37% | 21.71% | 22.20% | 22.60% | 22.44% |
| Operating Margin | -3.03% | 1.22% | -1.85% | -1.48% | 1.80% | -0.08% |
| Profit Margin | -5.10% | 0.69% | -1.81% | -1.78% | 1.00% | -1.53% |
| Free Cash Flow Margin | -1.06% | -1.52% | -3.63% | 1.96% | -3.10% | 4.15% |
| EBITDA | -10,679 | 18,655 | -4,446 | -1,247 | 21,420 | 7,202 |
| EBITDA Margin | -1.52% | 2.57% | -0.62% | -0.18% | 3.10% | 1.07% |
| D&A For EBITDA | 10,549 | 9,767 | 8,886 | 9,133 | 8,993 | 7,747 |
| EBIT | -21,228 | 8,888 | -13,332 | -10,380 | 12,427 | -544.94 |
| EBIT Margin | -3.03% | 1.22% | -1.85% | -1.48% | 1.80% | -0.08% |
| Effective Tax Rate | - | - | - | - | 44.51% | - |
| Advertising Expenses | - | 9,309 | 11,786 | 14,512 | 14,968 | 16,269 |
Source: S&P Capital IQ. Standard template. Financial Sources.